APYX
Apyx Medical Corp
$4.69
+0.86%
$196.4M
No data for this timeframe.
Vol
Market Cap$196.4M
Cap SizeMicro Cap
Inst. Holders25 funds
Inst. Value$29.3M
Inst. Activity5 buys / 2 sells
SEC Reports3
Press Releases3
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0000719135·Prev Close $4.65
Recent Activity
May 21, 2026
SEC
Apyx Medical announced the publication of a small (22-patient) investigator-initiated study in Aesthetic Surgery Journal
8-K — Impact 3/10
May 14, 2026
SEC
Apyx Medical announced the publication of a retrospective investigator-initiated study in *Plastic and Reconstructive Su
8-K — Impact 4/10
May 11, 2026
SEC
Apyx Medical received expanded FDA 510(k) clearance for its AYON Body Contouring System to include power liposuction, ad
8-K — Impact 6/10
Mar 15, 2026
Insider
CITRONOWICZ MOSHE acquired via exercise 37,000 shares
Senior Vice President @ $1.80 ($66.6K)
Inst.
SEI INVESTMENTS CO — DOUBLED
598,255 shares ($2.2M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
302,395 shares ($1.1M)
May 21, 2026
Press
Apyx Medical announced publication of a clinical study in Aesthetic Surgery Journal Open Forum showing that combining Av
Impact 3/10
May 21, 2026
fda
New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®
Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$6.50 (Mar 2026)
Current $4.69
Low $6.00
Median $6.00
High $8.00
4 analysts
$6.00
$8.00
Analyst Ratings
3Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 11, 2026 | Craig-Hallum | MAINTAIN | Buy → Buy |
| Mar 11, 2026 | BTIG | UPGRADE | Neutral → Buy |
| Dec 16, 2025 | Roth Capital | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.09 ▲ +2.8% | $-0.10 — $-0.08 | 3% YoY | 4 |
| Next Q | $-0.09 ▼ -12.8% | $-0.12 — $-0.07 | -85% YoY | 4 |
| Current FY | $-0.28 ▲ +13.0% | $-0.31 — $-0.25 | -4% YoY | 4 |
| Next FY | $-0.26 ▲ +6.9% | $-0.31 — $-0.20 | 6% YoY | 4 |
Latest Reports
NEUTRAL
8-K
3/10
Apyx Medical announced the publication of a small (22-patient) investigator-initiated study in Aesthetic Surgery Journal
May 21, 2026
NEUTRAL
Press
3/10
Apyx Medical announced publication of a clinical study in Aesthetic Surgery Journal Open Forum showing that combining Av
May 21, 2026
NEUTRAL
8-K
4/10
Apyx Medical announced the publication of a retrospective investigator-initiated study in *Plastic and Reconstructive Su
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYCE & ASSOCIATES LP | $9.6M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.7M | — |
| COMMONWEALTH EQUITY SERVICES, LLC | $2.4M | — |
| HORIZON KINETICS ASSET MANAGEMENT | $2.3M | — |
| SEI INVESTMENTS CO | $2.2M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 15, 2026 | CITRONOWICZ MOSHE | M | $66.6K |
25 institutional holders with $29.3M total value (7,938,598 shares) as of 2026-Q1. Top holders: ROYCE, VANGUARD, COMMONWEALTH. Net buying activity: 5 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYCE & ASSOCIATES LP | 2,611,224 | $9.6M | 32.9% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,555,272 | $5.7M | 19.6% | — |
| 3 | COMMONWEALTH EQUITY SERVICES, LLC | 649,061 | $2.4M | 8.2% | — |
| 4 | HORIZON KINETICS ASSET MANAGEMENT LLC | 615,000 | $2.3M | 7.7% | — |
| 5 | SEI INVESTMENTS CO | 598,255 | $2.2M | 7.5% | DOUBLED +298.6% |
| 6 | BlackRock, Inc. | 527,748 | $1.9M | 6.6% | — |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 302,395 | $1.1M | 3.8% | ADD +37.2% |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 267,561 | $987.3K | 3.4% | — |
| 9 | VANGUARD FIDUCIARY TRUST CO | 202,681 | $747.9K | 2.6% | — |
| 10 | STATE STREET CORP | 120,206 | $443.6K | 1.5% | — |
| 11 | CITADEL ADVISORS LLC | 107,798 | $397.8K | 1.4% | DOUBLED +283.8% |
| 12 | GOLDMAN SACHS GROUP INC | 73,923 | $272.8K | 0.9% | — |
| 13 | MARSHALL WACE, LLP | 61,836 | $228.2K | 0.8% | TRIM -42.7% |
| 14 | Hudson Bay Capital Management LP | 54,001 | $199.3K | 0.7% | DOUBLED +160.6% |
| 15 | MORGAN STANLEY | 51,627 | $190.5K | 0.7% | DOUBLED +114.5% |
| 16 | Centiva Capital, LP | 41,021 | $151.4K | 0.5% | — |
| 17 | Point72 Asset Management, L.P. | 34,778 | $128.3K | 0.4% | ADD +56.7% |
| 18 | FRANKLIN RESOURCES INC | 20,109 | $74.2K | 0.3% | — |
| 19 | CITIGROUP INC | 15,797 | $58.3K | 0.2% | — |
| 20 | OMERS ADMINISTRATION Corp | 12,000 | $44.3K | 0.2% | TRIM -62.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| SEI INVESTMENTS CO | DOUBLED | 150,081 | 598,255 | +298.6% | $2.2M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 220,395 | 302,395 | +37.2% | $1.1M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 107,875 | 61,836 | -42.7% | $228.2K | 2026-Q1 |
| Hudson Bay Capital Management LP | DOUBLED | 20,719 | 54,001 | +160.6% | $199.3K | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 24,069 | 51,627 | +114.5% | $190.5K | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 22,187 | 34,778 | +56.7% | $128.3K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 31,722 | 12,000 | -62.2% | $44.3K | 2026-Q1 |
| MORGAN STANLEY | ADD | 13,665 | 24,069 | +76.1% | $84.2K | 2025-Q4 |
| GROUP ONE TRADING LLC | DOUBLED | 1,792 | 11,444 | +538.6% | $40.1K | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 75,299 | 24,664 | -67.2% | $52.8K | 2025-Q3 |
| UBS Group AG | DOUBLED | 405 | 12,716 | +3039.8% | $27.2K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 4,308 | 405 | -90.6% | $911.00 | 2025-Q2 |
| Rathbones Group PLC | TRIM | 251,334 | 101,334 | -59.7% | $160.1K | 2024-Q4 |
| UBS Group AG | DOUBLED | 705 | 3,851 | +446.2% | $6.1K | 2024-Q4 |
| GROUP ONE TRADING LLC | TRIM | 3,747 | 2,393 | -36.1% | $3.8K | 2024-Q4 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | TRIM | 157,946 | 90,798 | -42.5% | $112.6K | 2024-Q3 |
| CITADEL ADVISORS LLC | DOUBLED | 3,276 | 12,573 | +283.8% | $15.6K | 2024-Q3 |
1 unique insiders with 1 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 15, 2026 | CITRONOWICZ MOSHE | Senior Vice President | EXERCISE | 37,000 | $1.80 | $66.6K |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
8-K
3/10
Apyx Medical announced the publication of a small (22-patient) investigator-initiated study in Aesth
May 21, 2026
NEUTRAL
8-K
4/10
Apyx Medical announced the publication of a retrospective investigator-initiated study in *Plastic a
May 14, 2026
BULLISH
8-K
6/10
Apyx Medical received expanded FDA 510(k) clearance for its AYON Body Contouring System to include p
May 11, 2026
NEUTRAL
3/10
Apyx Medical announced publication of a clinical study in Aesthetic Surgery Journal Open Forum showi
May 21, 2026
NEUTRAL
3/10
Apyx Medical announced it will release its Q1 fiscal 2026 financial results on May 7, 2026, followed
Apr 23, 2026
BULLISH
8/10
Apyx Medical reported record Q4 2025 revenue of $19.2 million, up 34.7% year-over-year, driven by st
Mar 10, 2026
Historical analyst distribution (last covering-analyst action Mar 2026): 90% buy across 10 analysts — 3 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$6.50 mean target (Mar 2026)
$6.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $4.69 |
| Target Low | $6.00 |
| Target Mean | $6.50 |
| Target Median | $6.00 |
| Target High | $8.00 |
| # Analysts | 4 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.09 | $-0.10 | $-0.08 | 2.8% | +2.8% | 4↑ 0↓ | $0.0B | 17.2% | 4 |
| Next Q 2026-09-30 |
$-0.09 | $-0.12 | $-0.07 | -85.0% | -12.8% | 4↑ 0↓ | $0.0B | 6.0% | 4 |
| Current FY 2026-12-31 |
$-0.28 | $-0.31 | $-0.25 | -3.7% | +13.0% | 4↑ 0↓ | $0.1B | 12.7% | 4 |
| Next FY 2027-12-31 |
$-0.26 | $-0.31 | $-0.20 | 6.3% | +6.9% | 3↑ 0↓ | $0.1B | 10.4% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.087 | |
| 7d ago | $-0.087 | |
| 30d ago | $-0.090 | +0.003 |
| 60d ago | $-0.090 | +0.003 |
| 90d ago | $-0.100 | +0.013 |
3 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 11, 2026 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | BTIG | UPGRADE | Neutral | Buy |
| Dec 16, 2025 | Roth Capital | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Jan 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 21, 2026
fda
New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®
Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach <pre>Published data demo
May 11, 2026
other
Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™
Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON <pre>A
May 7, 2026
earnings
Apyx Medical Corporation Reports First Quarter 2026 Financial Results
<p align="justify">CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the “
May 7, 2026
earnings_calendar
APYX Q1 2026 Earnings Before Market Open — 2026-05-07
Apr 23, 2026
announcement
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
<p>CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (NASDAQ:APYX)</strong> (the “Company” or “Apyx Medical”), t
Mar 10, 2026
announcement
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
<p align="justify">CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- <strong>Apyx Medical Corporation (NASDAQ:APYX)</strong> (“Apyx Medical;” the
Mar 10, 2026
earnings_calendar
APYX Q4 2025 Earnings After Market Close — 2026-03-10